Healthcare / BiotechnologyNasdaqCM
$10.11
-0.30 (-2.88%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-27.2M · quality 52.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
17/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$91M
P/E
N/A
•EV/EBITDA
N/A
•ROE
3155.8%
↑Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2025 · 4 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.71x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-39.7M · FCF $-28.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Net Income | $-39.7M | $-39.7M | $2.8M | $-13.2M | $-18.1M | $-9.8M |
| EBITDA | $-39.7M | $-39.7M | $2.9M | $-13.0M | $-17.8M | — |
| EPS | -22.61 | -22.61 | 2.63 | -26.75 | -60.25 | -42.25 |
| Balance Sheet | ||||||
| Debt/Equity | — | — | — | — | — | 0.69 |
| Current Ratio | 9.92 | 9.92 | — | — | — | — |
| Cash Flow | ||||||
| Free Cash Flow | $-28.1M | $-28.1M | $-27.2M | $-10.8M | $-17.0M | $-9.3M |
| Returns | ||||||
| ROE | 3155.8% | 3155.8% | 16.9% | -352.0% | 1340.2% | -173.0% |
| Valuation | ||||||
| P/E | — | — | 9.89 | — | — | — |
| EV/EBITDA | — | — | 4.98 | — | — | — |
| P/B | — | — | 1.67 | 4.55 | — | — |
| Growth & Yield | ||||||
| EPS Growth | -959.7% | -959.7% | 109.8% | 55.6% | — | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-19.1%
Start / end P/E
n/dx → n/dx
EPS bridge
2.63 → -22.61
Residual
-19.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.